ACADIA Pharmaceuticals Inc Q1 2021 Earnings Call Summary - Thomson StreetEvents

ACADIA Pharmaceuticals Inc Q1 2021 Earnings Call Summary

ACADIA Pharmaceuticals Inc Q1 2021 Earnings Call Summary - Thomson StreetEvents
ACADIA Pharmaceuticals Inc Q1 2021 Earnings Call Summary
Published May 05, 2021
20 pages (10361 words) — Published May 05, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of ACAD.OQ earnings conference call or presentation 5-May-21 9:00pm GMT

  
Brief Excerpt:

...A. Highlights: Remains steadfast in commitment to mission and to executing on three strategic pillars to create long-term growth. 1. Driving continued growth of NUPLAZID for patients with Parkinson's disease psychosis (PDP). a. b. Delivering on dementia-related psychosis (DRP) opportunity. c. Developing next wave of breakthrough therapies by advancing development pipeline and acquiring new assets. 2. NUPLAZID: Net sales $106.6m. a. Up 18% YoverY driven by strong YoverY performance in office-based setting. i. ii. Negatively impacted by post-holiday spike of COVID-19 and ongoing conditions relating to pandemic. b. Looking ahead, observed improvements related to pandemic in latter part of 1Q and into beginning of 2Q. i. Based on these indicators, projecting continued growth throughout year and reiterating net sales guidance for FY21 at $510-550m. 3. DRP program update: Remains committed to bringing pimavanserin to DRP patient community. a. b. In April, announced that FDA issued complete response...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
ACADIA Pharmaceuticals Inc
Ticker
ACAD.OQ
Time
9:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Steve and team, thank you for the update. Steve, I just wanted to focus a bit on the near-term outlook for PDP. It sounds like you had an encouraging exit -- first quarter metrics and the reiteration of the full year guidance. I'm just curious if you could just touch a little bit more on those factors. If I heard Elena correctly, I think she indicated that maybe a lower end of the range. So just curious if you could maybe unpack that a bit, maintaining that guidance versus perhaps narrowing that or lowering it just in light of the commentary you added. And then just lastly, related to that, just curious, to what degree, if any, was the DRP opportunity this year a potential potentiator for PDP penetration in the market?

Table Of Contents

ACADIA Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript – 2021-06-08 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 8-Jun-21 6:10pm GMT

ACADIA Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript – 2021-06-02 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 2-Jun-21 5:30pm GMT

ACADIA Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript – 2021-05-18 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 18-May-21 7:05pm GMT

ACADIA Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript – 2021-05-12 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 12-May-21 6:45pm GMT

ACADIA Pharmaceuticals Inc Q1 2021 Earnings Call Transcript – 2021-05-05 – US$ 54.00 – Edited Transcript of ACAD.OQ earnings conference call or presentation 5-May-21 9:00pm GMT

ACADIA Pharmaceuticals Inc To Discuss Complete Response Letter from U.S. FDA for Supplemental New Drug Application Summary – 2021-04-05 – US$ 54.00 – Edited Brief of ACAD.OQ conference call or presentation 5-Apr-21 12:00pm GMT

ACADIA Pharmaceuticals Inc To Discuss Complete Response Letter from U.S. FDA for Supplemental New Drug Application Transcript – 2021-04-05 – US$ 54.00 – Edited Transcript of ACAD.OQ conference call or presentation 5-Apr-21 12:00pm GMT

ACADIA Pharmaceuticals Inc Corporate Call - Regulatory Update on Supplemental New Drug Application Summary – 2021-03-08 – US$ 54.00 – Edited Brief of ACAD.OQ conference call or presentation 8-Mar-21 10:00pm GMT

ACADIA Pharmaceuticals Inc Corporate Call - Regulatory Update on Supplemental New Drug Application Transcript – 2021-03-08 – US$ 54.00 – Edited Transcript of ACAD.OQ conference call or presentation 8-Mar-21 10:00pm GMT

ACADIA Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript – 2021-03-01 – US$ 54.00 – Edited Transcript of ACAD.OQ presentation 1-Mar-21 5:20pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "ACADIA Pharmaceuticals Inc Q1 2021 Earnings Call Summary" May 05, 2021. Alacra Store. May 12, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2021-ACADIA-Pharmaceuticals-Inc-Earnings-Call-B14671608>
  
APA:
Thomson StreetEvents. (2021). ACADIA Pharmaceuticals Inc Q1 2021 Earnings Call Summary May 05, 2021. New York, NY: Alacra Store. Retrieved May 12, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2021-ACADIA-Pharmaceuticals-Inc-Earnings-Call-B14671608>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.